MAP
TAK icon

Managed Asset Portfolios’s Takeda Pharmaceutical TAK Stock Holding History

Managed Asset Portfolios’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
1,823,884
+25,486
+1% +$422K 3.34% 9
2026
Q1 		$33.3M Buy
1,798,398
+302,652
+20% +$5.31M 3.99% 5
2025
Q4 		$23.3M Buy
1,495,746
+9,338
+0.6% +$134K 2.82% 13
2025
Q3 		$21.8M Sell
1,486,408
-2,435
-0.2% -$36.2K 2.69% 17
2025
Q2 		$23M Buy
1,488,843
+19,177
+1% +$283K 2.99% 15
2025
Q1 		$21.9M Buy
1,469,666
+52,218
+4% +$732K 3.03% 13
2024
Q4 		$18.8M Sell
1,417,448
-200,093
-12% -$2.75M 2.78% 16
2024
Q3 		$23M Buy
1,617,541
+4,069
+0.3% +$57.7K 3.25% 14
2024
Q2 		$20.9M Sell
1,613,472
-70,204
-4% -$929K 3.1% 16
2024
Q1 		$23.4M Sell
1,683,676
-74,405
-4% -$1.08M 3.4% 13
2023
Q4 		$25.1M Buy
1,758,081
+21,665
+1% +$307K 3.8% 9
2023
Q3 		$26.9M Buy
1,736,416
+25,291
+1% +$392K 4.12% 7
2023
Q2 		$26.9M Buy
1,711,125
+243,173
+17% +$3.98M 4.04% 8
2023
Q1 		$24.2M Sell
1,467,952
-1,476
-0.1% -$23.5K 3.67% 11
2022
Q4 		$22.9M Buy
1,469,428
+7,614
+0.5% +$106K 3.58% 11
2022
Q3 		$19M Buy
1,461,814
+17,013
+1% +$237K 3.36% 11
2022
Q2 		$20.3M Buy
1,444,801
+44,923
+3% +$641K 3.22% 15
2022
Q1 		$20M Buy
1,399,878
+233,850
+20% +$3.43M 2.75% 19
2021
Q4 		$15.9M Sell
1,166,028
-49,721
-4% -$697K 2.25% 21
2021
Q3 		$19.9M Buy
1,215,749
+9,561
+0.8% +$161K 3.03% 17
2021
Q2 		$20.3M Buy
1,206,188
+140,432
+13% +$2.39M 3.02% 17
2021
Q1 		$19.5M Buy
1,065,756
+99,113
+10% +$1.78M 3.13% 16
2020
Q4 		$17.6M Buy
966,643
+54,659
+6% +$959K 3.09% 16
2020
Q3 		$16.3M Buy
911,984
+327,808
+56% +$5.97M 3.24% 16
2020
Q2 		$10.5M Buy
584,176
+274,901
+89% +$4.94M 2.27% 21
2020
Q1 		$4.7M Buy
+309,275
New +$5.61M 1.25% 21

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Managed Asset Portfolios's TAK Position: Q2 2026 in Review

Managed Asset Portfolios increased its Takeda Pharmaceutical (TAK) stake by 1.4% in Q2 2026, buying an estimated $422K and bringing the position to 1,823,884 shares worth $29.2M. The position accounts for 3.34% of the portfolio, ranked #9.

Managed Asset Portfolios first reported a position in TAK in Q1 2020 and has held it in 26 quarters since. The position peaked at $33.3M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Managed Asset Portfolios held 1,823,884 shares of Takeda Pharmaceutical worth $29.2M as of Q2 2026.
  • Managed Asset Portfolios bought 25,486 Takeda Pharmaceutical shares in Q2 2026, an estimated $422K.
  • Takeda Pharmaceutical made up 3.34% of Managed Asset Portfolios's portfolio in Q2 2026, its #9 holding.
  • Managed Asset Portfolios first reported a position in Takeda Pharmaceutical in Q1 2020 and has held it in 26 quarters since.
  • Managed Asset Portfolios's Takeda Pharmaceutical position peaked at $33.3M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Managed Asset Portfolios's 13F filing for Q2 2026, filed 6 Aug 2026.